STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer — A Multi-Arm Multi-Stage Randomised Controlled Trial

Nicholas D. James(Royal Marsden NHS Foundation Trust), Mahesh KB Parmar(MRC Clinical Trials Unit at UCL), R.C. Morgan(MRC Clinical Trials Unit at UCL), Matthew R. Sydes(Cancer Research UK), Noel W. Clarke(Salford Royal NHS Foundation Trust), R. Popert(St Thomas' Hospital), John Dwyer, John Anderson(Royal Hallamshire Hospital), D.P. Dearnaley(Royal Marsden NHS Foundation Trust), K.E. Sanders(MRC Clinical Trials Unit at UCL), Jonathan Masters(University College London), M. Mason(Cardiff University), J. M. Stansfeld
Clinical Oncology
August 30, 2008
10.1016/j.clon.2008.07.002
Cited by 55

Related Papers

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular Cancer
|Journal of Clinical Oncology|2003|548
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
|The Lancet Oncology|2014|491
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419